Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quarterly results round-up: Boston swings to loss on goodwill charge, COV, BCR, ROG, ZMH

This article was originally published in Clinica

Executive Summary

Boston Scientific has had a poor second fiscal quarter, seeing revenues shrink 7% and swinging to a net loss. Q2 sales were $1.83bn versus $1.98bn during the same period last year, weighed down by declines in the firm's two biggest units, interventional cardiology (-16% to $549m) and cardiac rhythm management (CRM, -10% to $488m). These businesses have been weak for some time – in Q1, sales fell 5% to $603m and 10% to $501m, respectively (www.clinica.co.uk, 20 April 2012).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel